| 영문 | neonatal intensive care center | 한글 | 신생아 집중치료실 |
|---|---|---|---|
| 설명 | 미숙아나 가사 상태의 출산아를 집중적으로 보살피고 치료하는 기관. |
||
| 영문 | insulin | 한글 | 인슐린 |
|---|---|---|---|
| 설명 | 이자 랑겔한스섬의 B세포가 합성-분비하는 호르몬 단백질, 포도당을 글리코겐으로 바꾸는 호르몬단백질로, 분자량은 5,807이다. 혈중의 당농도 상승으로 인하여 분비가 촉진된다. 근육-지방조직-간 등 표적세포의 수용체 단백질과 결합하여 정보를 세포내로 전달함으로써 혈액 중에서 당, 지질, 아미노산 대사를 조절한다. 당의 조직에 받아드리는 것을 촉진하여 혈당을 저하시킨다. 생성-분비량 저하, 조직세포의 수용체 부족은 고혈당의 원인이 된다. 또한 아미노산의 흡수와 단백질, 지방의 합성을 촉진하며 지방분해는 억제한다. 인슐린은 이자활성성분의 약품으로서 당뇨병 및 기타 질환의 치료에 사용된다. 인슐린이라는 명칭은 섬이란 뜻의 라틴어인 insula에서 연유한다. 1921년 캐나다의 의사 F.G. 밴팅과 C.H. 베스트에 의하여 처음으로 이자에서 채취되었고, 그 후 인슐린의 결정을 얻게 되었다. F. 생거에 의해서 소의 인슐린의 구조가 밝혀졌는데(1955), 이것은 단백질 중에서는 최초로 구조식이 밝혀진 것이다. 포도당으로부터 글리코겐의 생성, 포도당의 산화 및 지방으로의 전화 등을 촉진하는 작용이 있다. 따라서 인슐린의 수용액을 주사하면 혈당이 저하하므로 당뇨병의 치료에 쓰인다. 또 인슐린을 피하에 대량 주사하면 혼수에 빠지는 것을 이용하여 정신병 치료에 인슐린쇼크요법으로서 쓰인다. |
||
| 영문 | IDDM(Insulin-Dependent Diabetes Mellitus) | 한글 | 인슐린의존당뇨병 |
|---|---|---|---|
| 설명 | IDDM은 당뇨병의 치료에 반드시 인슐린이 필요한 경우를 말한다. 주로 원인이 이자에 있는 인슐린을 분비하는 세포의 파괴이며 이로 인해서 당뇨병의 치료제로 쓰이는 인슐린의 분비를 촉진하는 약물이 이 IDDM에서는 쓰일 수가 없고 오직 인슐린만이 치료제로 쓸 수가 있다. 전형적인 인슐린 의존형 당뇨병은 소아에서 흔히 발생하고 인슐린 분비세포의 파괴에 의해서 인슐린 분비능은 거의 없다. |
||
| 영문 | intensive care unit | 한글 | 중환자실 |
|---|---|---|---|
| 설명 | 병세나 상처 따위의 정도가 매우 심한 사람을 치료하고 돌볼 수 있도록 마련한 방. 호흡-순환-대사 등 정신적 급성기능상실의 환자를 취급하며 강력하고도 집중적인 진료를 하는 부분이다. 위독한 환자에 대하여는 24시간 체제로 대응한다. 충분히 훈련을 받은 의료진이 배치되며 기능적으로 설비가 갖추어져 있다. 심근경색증-호흡기능상실-콩팥기능상실-소아-신경외과계 등 특정환자를 대상으로 한다. |
||
| misc | miscarriage; miscellaneous |
|---|---|
| ACI | acceleration index; acoustic comfort index; acute cardiac ischemia; acute coronary infarction; acute... |
| CMO | cardiac minute output; Chief Medical Officer; comfort measures only; competitive medical organizatio... |
| FPCA | family practice comfort assessment |
| CCC | care-cure coordination; cathodal closure contraction; chronic calculous cholecystitis; chronic catar... |
| ACCESS | Access to Community Care and Effective Services and Support |
|---|---|
| ACNP | Acute Care Nurse Practitioner |
| ADHC | Adult Day Health Care |
| AHCPR | Agency for Health Care Policy and Research |
| AHRQ | Agency for Health Care Research and Quality |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| comfort zone | The temperature range between 28캜 and 30캜 at which the naked body is able to maintain the heat balance without either shivering or sweating; in the clothed body the range is from 13캜 to 21캜. (05 Mar 2000) |
|---|---|
| amorphous insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| anti-insulin | A factor, usually an antibody, which antagonises the action of insulin. (05 Mar 2000) |
| anti-insulin antibody | A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result. (27 Sep 1997) |
| biphasic insulin | <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin. (09 Oct 1997) |
| receptors, insulin | Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
| regular insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |
| regular insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| globin insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |
| globin zinc insulin | A sterile solution of insulin modified by the addition of zinc chloride and globin; it contains 40 or 80 units per ml; duration of action is about 18 hours. Human insulin, a protein that has the normal structure of insulin produced by the human pancreas, prepared by recombinant DNA techniques and by semisynthetic processes. Immunoreactive insulin (IRI), that portion of insulin in blood measured by immunochemical methods for the hormone; presumed to represent the free (unbound) and biologically active fraction of total blood insulin. Isophane insulin, a modified form of insulin composed of insulin, protamine, and zinc; an intermediately acting preparation used for the treatment of diabetes mellitus. Synonym: NPH insulin. (05 Mar 2000) |
| crystalline insulin zinc suspension | A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours. Synonym: crystalline insulin zinc suspension. (05 Mar 2000) |
| prompt insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| protamine zinc insulin | Insulin modified by the addition of protamine and zinc chloride; it contains 40 or 80 units per ml. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|